Championing Thrombosis and Hemostasis Policy Across Europe
The European Thrombosis and Haemostasis Alliance (ETHA) unites leading organizations to advance policy, education and research in thrombosis and hemostasis. We advocate for evidence-based strategies that improve patient outcomes
and support health equity across Europe.
What We Do
The European Thrombosis and Haemostasis Alliance (ETHA) brings together 28 leading organizations to ensure thrombosis and hemostasis are prioritized in EU health and patient safety agendas. We drive change by:
-
Advocate for stronger EU policies to improve prevention, diagnosis and treatment of bleeding and clotting disorders.
-
Collaborate with EU institutions, Members of the European Parliament (MEPs), regulatory agencies and health alliances to influence legislation, policy and funding decisions.
-
Advance research, education and clinical standards to promote high-quality, equitable care across Europe.
Founded by the International Society on Thrombosis and Haemostasis (ISTH), the ETHA operates as a pan-European alliance to lead advocacy efforts in thrombosis and hemostasis. This structure enables coordinated engagement with EU institutions and health stakeholders.
How ETHA Drives Impact
At ETHA, we focus on several key areas to achieve our mission:
Advance Research &
Innovation
We champion greater EU investment in thrombosis and hemostasis research, bringing scientists, clinicians and industry together to close evidence gaps and accelerate breakthroughs that benefit patients.
Educate Stakeholders and
Raise Awareness
We equip policymakers, healthcare professionals and the public with clear, actionable knowledge that improves prevention, diagnosis and care, turning scientific insight into life-saving practice.
Influence Policy through
Strategic Partnerships
We collaborate with EU institutions, MEPs and regulatory authorities—alongside our 28 member organisations and global allies—to secure policies, legislation and funding that keep thrombosis and hemostasis high on Europe’s health agenda.
OUR MISSION
The mission of the European Thrombosis and Haemostasis Alliance (ETHA) is to give the thrombosis and hemostasis community a voice and to drive prioritisation of thrombosis and hemostasis in the EU patient safety and research programs. With a united focus on raising awareness of bleeding and clotting disorders, ETHA stands together to work with the public as well as decision makers' to provide input into EU health and patient safety strategies.
ETHA is led by Mettine Bos, an Assistant Professor at the Leiden University Medical Center in The Netherlands, with Prof. Dr. Sabine Eichinger, Professor in the Department of Hematology and Hemostasis at the Medical University of Vienna, Austria, serving as Chair-Elect.
ETHA CONSENSUS STATEMENT
To learn more about ETHA’s initial areas of priority, read its consensus statement, here.
Our Approach
We take a collaborative and inclusive approach, working closely with a wide range of stakeholders—from governments and EU institutions to regulatory bodies and global health partners. Our efforts are grounded in excellence, integrity, and the pursuit of knowledge that drives real-world change for patients.
ETHA engages with decision-makers to elevate the importance of thrombosis and hemostasis in health policy. We advocate for increased research funding, improved clinical education, and greater public awareness—ensuring that these often-overlooked conditions receive the attention they deserve.
​
By aligning with the global thrombosis and hemostasis community and partnering across medical specialties, we advance shared priorities and integrated strategies. We also equip policymakers with evidence on the burden of thrombosis-related diseases and the impact of effective interventions.
​
Our ultimate goal: to position ETHA as a trusted voice and influential stakeholder in shaping EU policy on non-communicable diseases.
